Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HUM00224851 | Other Identifier | University of Michigan | |
| U01CA254822 | U.S. NIH Grant/Contract | View source | |
| HUM00221150 | Other Identifier | University of Michigan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
The Genetic Information and Family Testing (GIFT) Study is designed to support the capacity, opportunity, and motivation of cancer patients to engage their relatives about inherited cancer susceptibility and provide support and services to those relatives to initiate GRE (including genetic testing) and prepare them to subsequently engage their clinicians in informed decision-making about cancer prevention and early detection.
GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing. Two design features of the intervention will be randomized and evaluated to determine the best approach for future scalability.
Those eligible will be offered enrollment into the Michigan-hosted intervention trial, and those who enroll will be randomized into 1 of 4 study arms. Patients can invite their relatives to enroll and receive genetic testing via Color. Families randomized to the arms with human Navigator support will also have access to a Family Health Navigator at Stanford University. Enrolled patients and relatives will be surveyed six months post-enrollment to collect additional information regarding their interactions with the GIFT platform and their experiences with genetic risk evaluation.
Study phase and approximate sample size is summarized below:
Study phase and approximate sample size summarizes have been updated below and IRB approved 29SEP2025:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Other | Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted. |
|
| Arm 2 | Other | Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted. |
|
| Arm 3 | Other | Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted. |
|
| Arm 4 | Other | Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GIFT | Genetic | GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing. |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the independent effects of the two virtual platform design features on relatives' receipt of genetic testing. | The proportion of each enrolled patient's 1st and 2nd degree relatives who receive Color genetic testing through the GIFT platform. For each enrolled patient, this will be calculated as the number of enrolled relatives who obtain a genetic test result from Color (complete the genetic testing process) via the GIFT Study divided by the number of relatives reported on the baseline PICS survey. The endpoint of interest is the presence (as opposed to the absence) of a test result (e.g., positive, uncertain, negative) on the Color Quarterly Report. Assessed six months after the final relative enrolls in the study. | 6 months after the final relative enrolls |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the independent effects of the two virtual platform design features on the proportion of relatives invited by each patient to enroll in the study. | The proportion of each enrolled patient's relatives who are invited to join the study. For each enrolled patient: Number of invited relatives / Number of relatives reported on baseline PICS survey Assessed 91 days after the final patient enrolls in the study. |
Not provided
Inclusion criteria for the PICS survey are:
Additional eligibility criteria for Patient Trial Invitation will be evaluated from patient response to the PICS survey and will include patient report of:
Inclusion criteria for Relative Trial Invitation are assessed via patient report:
Additional eligibility criteria for Relative Trial Enrollment will be evaluated from relative response to the relative eligibility screening survey (see Appendix C) and will include:
Exclusion Criteria
Exclusion criteria for the PICS survey are:
1) Age<18
Additional exclusion criteria for Patient Trial Invitation:
Exclusion criteria for Relative Trial Invitation are:
Additional exclusion criteria for Relative Trial Enrollment include relative report of:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven Katz, MD | University of Michigan Rogel Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90007 | United States | ||
| Stanford University |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41875376 | Derived | Katz SJ, Hofer TP, Abrahamse P, Courser RR, Hodan R, Tocco RS, Rios-Ventura S, Ward KC, Hamilton AS, Frey MK, An LC, Kurian AW. Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial. J Clin Oncol. 2026 May;44(13):1216-1224. doi: 10.1200/JCO-25-02196. Epub 2026 Mar 24. | |
| 40016666 | Derived | Katz SJ, Abrahamse P, Hofer TP, Courser RR, Hodan R, Tocco RS, Rios-Ventura S, Ward KC, Hamilton AS, Kurian AW, An LC. The Genetic Information and Family Testing (GIFT) study: trial design and protocol. BMC Cancer. 2025 Feb 27;25(1):366. doi: 10.1186/s12885-025-13744-6. |
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 5, 2026 | |
| Reset | Jul 1, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 5, 2026 | Jul 1, 2026 |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
The trial is a 2x2 factorial prospective RCT
Not provided
Not provided
Randomization will be concealed from study participants; enrolled patients and relatives will not be aware that their family has been randomized into one of four trial arms and provided a different intervention experience than the other study participants. Concealment is necessary for this study so that the trial can observe differences across the trial arms without a) negatively impacting study enrollment and biasing the study, and b) causing unnecessary negative emotional reactions in study participants.
|
| 91 days after the final patient enrolls |
| To determine the independent effects of the two virtual platform design features on the cancer patients' assessment of communication with their relatives about hereditary cancer and genetic risk evaluation. | A 20-item scale with responses on a 5-point Likert from "not at all true" to "very true." Items assess patients' capacity, opportunity, and motivation to communicate with family members about their genetic test results. The outcome is continuous and we will measure the change in mean score from baseline to follow-up survey. A greater difference between timepoints will indicate greater improvement in the patient's assessment of their communication with relatives. Assessed at two time points: baseline PICS survey and Patient Six-Month Follow-up Survey. | After the 6 month follow up survey |
| To determine the independent effects of the two virtual platform design features on relatives' receipt of a formal cancer genetic counseling session in practice. | Single question on a binary yes/no scale. Yes will indicate receipt of formal GRE. Assessed in the Relative Six-Month Follow-Up Survey | After the 6 month follow up survey |
| Stanford |
| California |
| 94305 |
| United States |
| Emory University | Atlanta | Georgia | 30322 | United States |
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48108 | United States |